For U.S. Healthcare Professionals Only

Nicotinamide (NAM) Technology

Omisirge is the first and only FDA-approved, NAM-modified allogeneic hematopoietic progenitor cell (HPC) therapy for patients 12 years and older with hematologic malignancies in need of transplant

Click on the blue plus signs for more information

Donor source cells
are selected
Benefits of CBU as a
donor source
  • Less stringent HLA-matching requirements10
  • Enhanced graft-versus-
    leukemia (GvL) effect11
  • Rapid cell procurement12,13
  • No concern over
    donor age14
CD34+ Cells
(Cultured Fraction)
Cells are segregated
into two populations
according to their
expression of the stem
cell marker CD34
CD34- Cells
(Non-cultured Fraction)
Cells are washed, formulated into a
suspension, and then cryopreserved

CD34- Cells
(Non-cultured Fraction)

Cells are washed, formulated into a
suspension, and then cryopreserved

NAM-modified ex vivo expansion
increases the quantity and enhances
the functionality of HPCs15
Omisirge NAM-modified allogeneic
HPC therapy
CD34- Non-Cultured Fraction (NF)
Mature myeloid and lymphoid cells,
including T cells and B cells
CD34+ Cultured Fraction (CF)
Enhanced population of CD34+ HPCs

Find efficacy and safety information for Omisirge

  1. Kindwall-Keller TL et al. Oncologist. 2017;22(9):1125-1134. doi:10.1634/theoncologist.2017-0009
  2. How does a patient’s ethnic background affect matching? Published March 10, 2023.
  3. Fabricius WA et al. Adv Hematol. 2016;2016:5726132. doi:10.1155/2016/5726132
  4. Pidala J et al. Blood. 2014;124(16):2596-2606. doi:
  5. Horwitz ME et al. J Clin Oncol. 2019;37(5):367-374. doi:10.1200/JCO.18.00053
  6. Giralt S et al. Cancer Treat Res. 2009;144:1-21. doi:10.1007/978-0-387-78580-6_1
  7. Anthias C et al. Biol Blood Marrow Transplant. 2020;26(3):593-599. doi:10.1016/j.bbmt.2019.10.012
  8. You’re a Potential Match. Published June 2015
  9. Ciurea SO et al. Blood Adv. 2018;2(17):2254-2261. doi:10.1182/bloodadvances.2018021899
  10. Eapen M et al. Lancet Haematol. 2017;4(7):e325-e333. doi:10.1016/S2352-3026(17)30104-7
  11. Eapen M et al. Lancet. 2007;369(9577):1947-1954. doi:10.1016/S0140-6736(07)60915-5
  12. Wang JC et al. Blood. 1997;89(11):3919-3924
  13. Goussetis E et al. Cytotherapy. 2003;5(6):500-508. doi:10.1080/14653240310003602
  14. DeZern AE et al. Blood Adv. 2021;5(5):1360-1368. doi:10.1182/bloodadvances.2020003922
  15. Omisirge (omidubicel-onlv). Prescribing Information. Gamida Cell Ltd.; 2023.